365 related articles for article (PubMed ID: 30820738)
21. Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis.
Rose JW; Giovannoni G; Wiendl H; Gold R; Havrdová E; Kappos L; Selmaj KW; Zhao J; Riester K; Tsao LC; Greenberg SJ
Mult Scler Relat Disord; 2017 Oct; 17():32-40. PubMed ID: 29055471
[TBL] [Abstract][Full Text] [Related]
22. Clinical and MRI efficacy of sc IFN β-1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS.
Freedman MS; Brod S; Singer BA; Cohen BA; Hayward B; Dangond F; Coyle PK
J Neurol; 2020 Jan; 267(1):64-75. PubMed ID: 31559532
[TBL] [Abstract][Full Text] [Related]
23. Ocrelizumab: A Review in Multiple Sclerosis.
Syed YY
CNS Drugs; 2018 Sep; 32(9):883-890. PubMed ID: 30171504
[TBL] [Abstract][Full Text] [Related]
24. Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1.
Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A
BMC Neurol; 2018 Sep; 18(1):143. PubMed ID: 30217172
[TBL] [Abstract][Full Text] [Related]
25. Peginterferon beta-1a reduces the evolution of MRI lesions to black holes in patients with RRMS: a post hoc analysis from the ADVANCE study.
Arnold DL; You X; Castrillo-Viguera C
J Neurol; 2017 Aug; 264(8):1728-1734. PubMed ID: 28685353
[TBL] [Abstract][Full Text] [Related]
26. Matching-adjusted comparisons demonstrate better clinical outcomes with SC peginterferon beta-1a every two weeks than with SC interferon beta-1a three times per week.
Coyle PK; Shang S; Xiao Z; Dong Q; Castrillo-Viguera C
Mult Scler Relat Disord; 2018 May; 22():134-138. PubMed ID: 29679749
[TBL] [Abstract][Full Text] [Related]
27. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
Sorensen PS; Mellgren SI; Svenningsson A; Elovaara I; Frederiksen JL; Beiske AG; Myhr KM; Søgaard LV; Olsen IC; Sandberg-Wollheim M
Lancet Neurol; 2009 Jun; 8(6):519-29. PubMed ID: 19409854
[TBL] [Abstract][Full Text] [Related]
28. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
[TBL] [Abstract][Full Text] [Related]
29. Ocrelizumab exposure in relapsing-remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension.
Kappos L; Traboulsee A; Li DKB; Bar-Or A; Barkhof F; Montalban X; Leppert D; Baldinotti A; Schneble HM; Koendgen H; Sauter A; Wang Q; Hauser SL
J Neurol; 2024 Feb; 271(2):642-657. PubMed ID: 37906326
[TBL] [Abstract][Full Text] [Related]
30. Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE.
Kieseier BC; Arnold DL; Balcer LJ; Boyko AA; Pelletier J; Liu S; Zhu Y; Seddighzadeh A; Hung S; Deykin A; Sheikh SI; Calabresi PA
Mult Scler; 2015 Jul; 21(8):1025-35. PubMed ID: 25432952
[TBL] [Abstract][Full Text] [Related]
31. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
Cohen JA; Coles AJ; Arnold DL; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Fisher E; Brinar VV; Giovannoni G; Stojanovic M; Ertik BI; Lake SL; Margolin DH; Panzara MA; Compston DA;
Lancet; 2012 Nov; 380(9856):1819-28. PubMed ID: 23122652
[TBL] [Abstract][Full Text] [Related]
32. Ocrelizumab: A New B-cell Therapy for Relapsing Remitting and Primary Progressive Multiple Sclerosis.
Stahnke AM; Holt KM
Ann Pharmacother; 2018 May; 52(5):473-483. PubMed ID: 29232960
[TBL] [Abstract][Full Text] [Related]
33. Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS.
Arnold DL; Fisher E; Brinar VV; Cohen JA; Coles AJ; Giovannoni G; Hartung HP; Havrdova E; Selmaj KW; Stojanovic M; Weiner HL; Lake SL; Margolin DH; Thomas DR; Panzara MA; Compston DA;
Neurology; 2016 Oct; 87(14):1464-1472. PubMed ID: 27590291
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of subcutaneous interferon β-1a in relapsing-remitting multiple sclerosis: further outcomes from the IMPROVE study.
De Stefano N; Sormani MP; Stubinski B; Blevins G; Drulovic JS; Issard D; Shotekov P; Gasperini C
J Neurol Sci; 2012 Jan; 312(1-2):97-101. PubMed ID: 21880336
[TBL] [Abstract][Full Text] [Related]
35. Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials.
Giovannoni G; Kappos L; de Seze J; Hauser SL; Overell J; Koendgen H; Manfrini M; Wang Q; Wolinsky JS
Eur J Neurol; 2022 Apr; 29(4):1238-1242. PubMed ID: 33724637
[TBL] [Abstract][Full Text] [Related]
36. Ocrelizumab: A Review in Multiple Sclerosis.
Lamb YN
Drugs; 2022 Feb; 82(3):323-334. PubMed ID: 35192158
[TBL] [Abstract][Full Text] [Related]
37. Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study.
Lanzillo R; Quarantelli M; Bonavita S; Ventrella G; Lus G; Vacca G; Prinster A; Orefice G; Tedeschi G; Brescia Morra V
Acta Neurol Scand; 2012 Nov; 126(5):306-14. PubMed ID: 22107083
[TBL] [Abstract][Full Text] [Related]
38. Efficacy, safety and patient reported outcomes in patients with active relapsing multiple sclerosis treated with ocrelizumab: Final results from the PRO-MSACTIVE study.
Manchon E; Laplaud D; Vukusic S; Labauge P; Moreau T; Kobelt G; Grouin JM; Lotz M; Pau D; Christine LF
Mult Scler Relat Disord; 2022 Dec; 68():104109. PubMed ID: 36007299
[TBL] [Abstract][Full Text] [Related]
39. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.
Hutchinson M; Kappos L; Calabresi PA; Confavreux C; Giovannoni G; Galetta SL; Havrdova E; Lublin FD; Miller DH; O'Connor PW; Phillips JT; Polman CH; Radue EW; Rudick RA; Stuart WH; Wajgt A; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA;
J Neurol; 2009 Mar; 256(3):405-15. PubMed ID: 19308305
[TBL] [Abstract][Full Text] [Related]
40. An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability.
Wolinsky JS; Engmann NJ; Pei J; Pradhan A; Markowitz C; Fox EJ
Mult Scler J Exp Transl Clin; 2020; 6(1):2055217320911939. PubMed ID: 32206332
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]